www.neurologylive.com
Open in
urlscan Pro
76.76.21.164
Public Scan
Submitted URL: http://neurologytimes.com/
Effective URL: https://www.neurologylive.com/
Submission: On October 27 via api from US — Scanned from CA
Effective URL: https://www.neurologylive.com/
Submission: On October 27 via api from US — Scanned from CA
Form analysis 1 forms found in the DOM
GET /search
<form method="GET" action="/search">
<div class="relative">
<div class="text-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6"><button aria-label="submit" type="submit" class="absolute block inset-0"><svg xmlns="http://www.w3.org/2000/svg"
class="text-gray-600 stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round">
<path stroke="none" d="M0 0h24v24H0z"></path>
<circle cx="10" cy="10" r="7"></circle>
<line x1="21" y1="21" x2="15" y2="15"></line>
</svg></button></div><input type="text" required="" name="searchTerm" class="block border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2" placeholder="Search">
</div>
</form>Text Content
News Media All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsNews NetworkNeurologyLive Peer ExchangeMedcast PodcastsMedcast VideosPeers & PerspectivesRoundtable Discussions Conferences Conference CoverageConference Listing CME/CEPartners Publications NeurologyLiveBridging the GapsInternational Journal of MS Care Resources Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsLive EventsNeurology ResourcesSponsoredVirtual Events Subscribe Choose Specialty Dementia and Alzheimer Disease Epilepsy Headache and MigraineHeadache and Migraine MS and Demyelinating DisordersMS and Demyelinating DisordersMS and Demyelinating DisordersMS and Demyelinating Disorders Movement DisordersMovement Disorders NeuromuscularNeuromuscularNeuromuscularNeuromuscular Sleep DisordersSleep DisordersSleep Disorders Stroke Spotlight - * FDA News * Expert Authors * AANEM 2024 * ECTRIMS 2024 * MDS 2024 * * * * * * * * Choose Specialty Dementia and Alzheimer Disease Epilepsy Headache and MigraineHeadache and Migraine MS and Demyelinating DisordersMS and Demyelinating DisordersMS and Demyelinating DisordersMS and Demyelinating Disorders Movement DisordersMovement Disorders NeuromuscularNeuromuscularNeuromuscularNeuromuscular Sleep DisordersSleep DisordersSleep Disorders Stroke * * * * * * * * * * Spotlight * News * Media * Conferences * CME/CE * Partners * Publications * Resources * Subscribe Advertisement -------------------------------------------------------------------------------- LATEST NEWS Investigational Nipocalimab Demonstrates Efficacy and Safety in Adolescent Population of Myasthenia Gravis By Marco Meglio October 26th 2024 In a small sample population of adolescents with myasthenia gravis, nipocalimab met its primary end point, showing a significant reduction in total serum immunoglobuin over a 24-week period. NeurologyLive® Friday 5 — October 25, 2024 By NeurologyLive® Staff October 25th 2024 Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 25, 2024. Study Findings Provide New Hope for Patients With Multiple Sclerosis By Suhayl Dhib-Jalbut, MD October 25th 2024 Multiple sclerosis affects nearly 3 million patients worldwide; new research is helping pave the way for developing new therapies and medications that get at the defining mechanisms that trigger immune regulation loss of this unpredictable central nervous system disease. The Potential of Device-Assisted Therapies in PD: Insights From the Phase 1/2 DIVE-I Trial By Marco Meglio October 25th 2024 David Devos, MD, PhD, a neuropharmacologist at the University of Lille, in France, discussed positive data from an early-stage study assessing InBrain Pharma’s device-assisted therapy in Parkinson disease. Expert Insight on Pivotal Phase 2 Data of AMX0035 in Wolfram Syndrome By Marco Meglio October 24th 2024 Fumihiko Urano, MD, PhD, principal investigator of the phase 2 HELIOS trial, discussed some of the notable findings from the study, as well as the potential of AMX0035 to treat patients with Wolfram syndrome. COVERAGE OF THE AMERICAN ASSOCIATION OF NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE 2024 MEETING Get expert-driven insight and coverage of key data and research straight from the conference floor in Savannah. Read Now CONFERENCE COVERAGE View All Investigational Nipocalimab Demonstrates Efficacy and Safety in Adolescent Population of Myasthenia Gravis By Marco Meglio October 26th 2024 In a small sample population of adolescents with myasthenia gravis, nipocalimab met its primary end point, showing a significant reduction in total serum immunoglobuin over a 24-week period. Future Plans and Clinical Promise of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS By Richard Nowak, MD, MS October 25th 2024 The director of the myasthenia gravis clinic at Yale University provided additional insight on the MINT study of inebilizumab in myasthenia gravis, some of the subanalyses within, and next plans in the drug’s development. [WATCH TIME: 5 minutes] How Vidofludimus Calcium Addresses Unmet Treatment Needs in Multiple Sclerosis: Andreas Muehler, MD, MBA By Robert Fox, MD Andreas Muehler, MD, MBA * Marco Meglio October 25th 2024 The chief medical officer at Immunic provided clinical insight on the dual mechanism of action of vidofludimus calcium, and how its positioned as a treatment option across all MS subtypes. [WATCH TIME: 3 minutes] The Potential of Device-Assisted Therapies in PD: Insights From the Phase 1/2 DIVE-I Trial By Marco Meglio October 25th 2024 David Devos, MD, PhD, a neuropharmacologist at the University of Lille, in France, discussed positive data from an early-stage study assessing InBrain Pharma’s device-assisted therapy in Parkinson disease. Video Series Effective Balance of Approved Therapies and Patient Preferences Long COVID’s Impact on the Brain, Specifically Cognitive Function Final Thoughts on Dravet Syndrome Management Use of Long-term NMOSD Data in Clinical Practice Long-term NMOSD Data Advocacy Groups and Integration of Wellness Strategies into Treatment for Parkinson’s Disease Unmasking Long COVID Through Understanding Prevalence and Diagnosis Dravet Syndrome and Caregiver Burdens Beyond the Guidelines: Monitoring and Defining SMA Progression Challenges Associated With Dravet Syndrome Treatment Adult-Onset SMA: Diagnosis and Best Practices for Clinicians Optimizing Treatment Access in SMA: Navigating Timing and Outcomes Meningococcal Infection and NMOSD Complement Inhibitors in NMOSD Newborn Screening for SMA: Clinical Recommendations and Considerations Video Interviews Phase 3 Program of Vidofludimus Calcium Continues, CHMP Recommends Approval for Eplontersen, Patient Dosing Commenced in Phase 1/2 Trial of ATX-01 Future Plans and Clinical Promise of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS How Vidofludimus Calcium Addresses Unmet Treatment Needs in Multiple Sclerosis: Andreas Muehler, MD, MBA Therapeutic Potential of EDG-5506 in Treating Becker Muscular Dystrophy: Joanne Donovan, MD, PhD Challenges and Opportunities of Adapting Medical Education in a Digital Age: Lawrence Robinson, MD Mechanism and Promise Behind XEN1101 in Focal Epilepsy: Jacqueline French, MD Highlighting More Risk Factors and Treatments in Updated Stroke Prevention Guidelines: Cheryl D. Bushnell, MD, MHS, FAHA Understanding the Approval of Once-Nightly Sodium Oxybate for Pediatric Narcolepsy: Anne Marie Morse, DO, FAASM New Treatment Guidelines for Restless Legs Syndrome and Shifting Away From Dopamine Agonists: John Winkelman, MD, PhD FDA Approves Lumyrz for Pediatric Narcolepsy, 24-Hour Foslevodopa/Foscarbidopa Gets FDA Greenlight, Oral Edaravone Fails in Phase 3 Study Therapeutic Potential of Self-Administered Subcutaneous Rozanolixizumab in Myasthenia Gravis: Rachana K. Gandhi Mehta, MBBS Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD Innovative MyClad Study Testing Cladribine Capsules in Generalized Myasthenia Gravis: Henry Kaminski, MD Understanding the Therapeutic Potential of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS HNSA-5487 Significantly Reduces IgG Levels, FDA Removes Hold on AOC 1001, DMD Gene Therapy Shows No Impact on Cardiac Outcomes Podcasts Special Episode: FDA Approves Sodium Oxybate for Pediatric Narcolepsy Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis Episode 124: Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy Episode 123: Previewing Cleveland Clinic's Epilepsy Summit Multisymptomatic Care in Parkinson's Disease Episode 122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease Episode 121: Understanding the Potential Cardiovascular Benefits of Low-Sodium Oxybate Sleeping Around the Podcast × NeurologyLive: Erenumab, Migraine, and Sleep Episode 120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve Continuing Medical Education VideoCME,NCPD Mastering MS: Translating Evidence into Optimal Management Plans View More MultimediaCME Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care View More In-Person + Virtual EventCME,NCPD Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis - Current Treatment and Emerging Con... November 12, 2024 Register Now! VideoCME,NCPD Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes View More Virtual EventCME,COPE 2024 Neuromuscular Summit November 20, 2024 View More VideoCME 5th Annual International Congress on the Future of Neurology® View More VideoCME Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II View More MultimediaCME Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management View More MOST RECENT Gene Therapy FLT201 Shows Promise in Early-Stage Study of Gaucher Disease By Marco Meglio October 24th 2024 Article Based on the positive data, the company plans to begin a phase 3 trial assessing FLT203 in patients with Gaucher disease type 1 in the second half of 2025. Special Episode: FDA Approves Sodium Oxybate for Pediatric Narcolepsy By Marco Meglio October 23rd 2024 Podcast Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Anne Marie Morse, DO, FAASM. [LISTEN TIME: 12 minutes] Patient Dosing Commenced for Phase 1/2 ArthemiR Trial of ATX-01 in Myotonic Dystrophy Type 1 By Marco Meglio October 23rd 2024 Article ArthemiR, a placebo-controlled study, primarily evaluates the safety of ATX-01 in myotonic dystrophy type 1, with other assessments that include target engagement and measures associated with muscle function. NeuroVoices: Lawrence Robinson, MD, on Innovating Educational Approaches for Neuromuscular Specialists By Marco Meglio October 23rd 2024 Article The senior scientist at Sunnybrook Research Institute in Toronto, Ontario, provided clinical insight on his lecture given at AANEM 2024, focusing on the challenges and opportunities of teaching the next generation of practitioners. Phase 3 ENSURE Program of Vidofludimus Calcium Continues Following Positive Futility Analysis By Marco Meglio October 22nd 2024 Article An IDMC review of unblinded interim data was positive and advised that the trials continue as planned, with time to first relapse up to 72 weeks as the primary end point. Eplontersen Gains Positive CHMP Approval Recommendation for ATTR Polyneuropathy By Marco Meglio October 22nd 2024 Article With the positive recommendation, it marks a key step toward eplontersen’s availability in Europe as a treatment for ATTR polyneuropathy. Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment By Daniel Ontaneda, MD, PhD Jeffrey Cohen, MD October 22nd 2024 Article The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes. Understanding Nipocalimab’s Impact on Myasthenia Gravis Using MG-ADL By Marco Meglio October 22nd 2024 Article Constantine Farmakidis, MD, an associate professor of neurology at the University of Kansas Medical Center, provided clinical commentary on a subanalysis of a phase 3 study assessing nipocalimab, an investigational agent, in generalized myasthenia gravis. Details Behind the Phase 3 MyClad Study of Cladribine in Myasthenia Gravis By Marco Meglio October 22nd 2024 Article Study investigator Henry Kaminski, MD, provided clinical insight on a unique trial assessing the efficacy and safety of oral cladribine tablets, an FDA-approved medication for multiple sclerosis, in patients with myasthenia gravis. Beyond Diagnosis: New Data Show Early Nerve Conduction Studies Predict Treatment Outcomes in CIDP By Marco Meglio October 21st 2024 Article The data shows that changes in neuropathy impairment scores using nerve conduction studies may forecast which patients will respond better to treatment. New Published Guideline Provides Recommendations for Primary Stroke Prevention Across Life Span By Isabella Ciccone, MPH October 21st 2024 Article The new guideline emphasized the importance of screening for risk factors and promoted healthy lifestyle changes to reduce the risk of stroke, which impacts over half a million patients in the United States. How America's Neurological Care Crisis is Reshaping Medicare and What That Means for You By Neal K. Shah October 21st 2024 Article Neal K. Shah, chief executive officer at CareYaya Health Technologies, talked about Medicare making big moves in neurological care. This Week on NeurologyLive® — October 21, 2024 By NeurologyLive® Staff October 21st 2024 Article Here's some of what is coming soon to NeurologyLive® this week. Subcutaneous Efgartigimod PH20 Efficacious in Patients With CIDP Previously Treated By Isabella Ciccone, MPH October 20th 2024 Article A recent analysis of the phase 3 ADHERE trial demonstrated the clinical benefit of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyneuropathy. NeurologyLive® Brain Games: October 20, 2024 By Marco Meglio October 20th 2024 Article Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Lennox-Gastaut syndrome. Clinical Insights From Phase 3 VIVACITY-MG3 Study of Nipocalimab in Generalized Myasthenia Gravis By Marco Meglio October 19th 2024 Article Tuan Vu, MD, a professor of neurology at the University of South Florida, provided brief commentary on topline data of the phase 3 VIVACITY-MG3 study presented at AANEM 2024. Phase 3 Trial to Assess Therapeutic Effect of IV Efgartigimod in Seronegative Myasthenia Gravis By Marco Meglio October 19th 2024 Article The phase 3 study is expected to include 110 patients with seronegative myasthenia gravis who will be randomly assigned to IV efgartigimod or placebo for a 5-week follow-up, followed by an open-label extension. RAISE-XT Interim Analysis Shows Sustained Efficacy of Long-Term Zilucoplan Treatment in Generalized Myasthenia Gravis By Isabella Ciccone, MPH October 18th 2024 Article A new analysis revealed zilucoplan’s long-term efficacy and safety in patients with generalized myasthenia gravis, with data extending to 120 weeks of treatment. NeurologyLive® Friday 5 — October 18, 2024 By NeurologyLive® Staff October 18th 2024 Article Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 18, 2024. Ranging Cycle Cadence of Rozanolixizumab Highlights Need for Individualized Treatment Approach By Marco Meglio October 18th 2024 Article Despite balanced baseline characteristics, patients ranged from low to high number of rozanolixizumab treatment cycles, suggesting the need for a personalized approach. Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy By Marco Meglio October 18th 2024 Podcast Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Claassen, MD, MS. [LISTEN TIME: 14 minutes] Phase 3b ADAPT NXT Study Confirms Efficacy of Cyclic and Biweekly Dosing of Efgartigimod in Generalized Myasthenia Gravis By Isabella Ciccone, MPH October 17th 2024 Article Findings showed that both fixed cycles and every-other-week dosing regimens of efgartigimod were well tolerated and effective in improving clinical outcomes in patients with generalized myasthenia gravis. Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis By Marco Meglio October 17th 2024 Article The PREVAIL trial, presented at the 2024 AANEM meeting, is investigating gefurulimab, a bispecific nanoantibody designed to inhibit complement activation, as a potential treatment for patients with generalized myasthenia gravis. FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy By Isabella Ciccone, MPH October 17th 2024 Article Sodium oxybate is the only FDA-approved once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in pediatric patients with narcolepsy. FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment By Isabella Ciccone, MPH October 17th 2024 Article In clinical trials, patients with Parkinson disease who were treated with foscarbidopa/foslevodopa experienced superior improvement in ON time without dyskinesia compared with oral immediate-release carbidopa/levodopa. See All News > Advertisement Latest SAP Content Mechanism and Promise Behind XEN1101 in Focal Epilepsy: Jacqueline French, MD Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment Beyond the Guidelines: Monitoring and Defining SMA Progression Adult-Onset SMA: Diagnosis and Best Practices for Clinicians View More SAP Content Advertisement Advertisement x About Us Advisory Board Editorial Contact Us Advertise Contact MJH LS Do Not Sell My Information Terms and Conditions Privacy Contact Info 2 Commerce Drive Cranbury, NJ 08512 609-716-7777 © 2024 MJH Life Sciences All rights reserved.